DNlite-IVD103 is a urinary ELISA kit that precisely manages Diabetic Kidney Disease (DKD). By detecting a specific urinary biomarker and meticulously monitoring for post translational modifications to the marker, DNlite-IVD103 can effectively predict the kidney condition of a diabetes patient over the 1-2 years that follow. If a risk of progressive Glomerular Filtration Rate (GFR) decline is detected, patients can be recommended to start proper treatment earlier, and seize a critical window for clinical action and even recovery. Prediction of decline or kidney complications will drastically improve the DKD patient’s quality of care. DNlite-IVD103 has obtained CE IVD mark, Malaysia MDA and other regulatory-approvals for global market. BPM is seeking worldwide distribution partner for DNlite-IVD103.
Subscribe to receive exclusive content and notifications to your inbox
